Cited by 112Tuberculosis Research and EpidemiologyCellular transport and secretionAutophagy in Disease and Therapy

Abelson Tyrosine Kinase Controls Phagosomal Acidification Required for Killing of Mycobacterium tuberculosis in Human Macrophages

Open access
Bruns, Heiko, Stegelmann, Frank, Fabri, Mario, Döhner, Konstanze, van Zandbergen, Ger, Wagner, Manfred, Skinner, Mhairi, Modlin, Robert L +1 more·2012·The Journal of Immunology

Abstract

The mechanisms that regulate the acidification of intracellular compartments are key to host defense against pathogens. In this paper, we demonstrate that Abl tyrosine kinase, a master switch for cell growth and trafficking of intracellular organelles, controls the acidification of lysosomes in human macrophages. Pharmacological inhibition by imatinib and gene silencing of Abelson (Abl) tyrosine kinase reduced the lysosomal pH in human macrophages by increasing the transcription and expression of the proton pumping enzyme vacuolar-type H+-adenosine triphosphatase. Because lysosomal acidification is required for antimicrobial activity against intracellular bacteria, we determined the effect of imatinib on the growth of the major human pathogen Mycobacterium tuberculosis. Imatinib limited the multiplication of M. tuberculosis, and growth restriction was dependent on acidification of the mycobacterial compartment. The effects of imatinib were also active in vivo because circulating monocytes from imatinib-treated leukemia patients were more acidic than monocytes from control donors. Importantly, sera from imatinib-treated patients triggered acidification and growth restriction of M. tuberculosis in macrophages. In summary, our results identify the control of phagosomal acidification as a novel function of Abl tyrosine kinase and provide evidence that the regulation occurs on the level of the vacuolar-type H+-adenosine triphosphatase. Given the efficacy of imatinib in a mouse model of tuberculosis and our finding that orally administered imatinib increased the ability of human serum to trigger growth reduction of intracellular M. tuberculosis, clinical evaluation of imatinib as a complementary therapy of tuberculosis, in particular multidrug or extremely drug-resistant disease, is warranted.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.4049/jimmunol.1201538

Cites

62 of 62 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Inhibition of Abl tyrosine kinase by imatinib resulted in increased acidification of the lysosome and improved control of M. tuberculosis.

    “Inhibition of Abl tyrosine kinase by the clinically used drug imatinib resulted in increased acidification of the lysosome and improved control of M. tuberculosis (39).”

    From Macrophage defense mechanisms against intracellular bacteria (2015) · cites this paper as [39]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 3

  1. [30]Van Etten RA Jackson PK Baltimore D Sanders MC Matsudaira PT Janmey PA The COOH terminus of the c-Abl tyrosine kinase contains distinct F- and G-actin binding domains with bundling activity J. Cell Biol 1994 124 325 340 8294516 PMC2119935
  2. [37]Bouley DM Ghori N Mercer KL Falkow S Ramakrishnan L Dynamic nature of host-pathogen interactions in Mycobacterium marinum granulomas Infect. Immun 2001 69 7820 7831 11705964 PMC98878
  3. [42]Vandal OH Nathan CF Ehrt S Acid resistance in Mycobacte-rium tuberculosis J. Bacteriol 2009 191 4714 4721 19465648 PMC2715723

Cited by

Sorted by citations

Authors
Bruns, H., Stegelmann, F., Fabri, M., Döhner, K., van Zandbergen, G., Wagner, M., Skinner, M., Modlin, R. L., & Stenger, S.
Affiliations
  • Universität Ulm (DE)
  • University Hospital Ulm (DE)
  • University of California, Los Angeles (US)
  • Institut für Medizinische Mikrobiologie und Hygiene, Universitätsklinikum Ulm , D-89081 Ulm,
  • Nuremberg Hospital (DE)
  • University of Guelph (CA)
Corresponding author
  • Bruns, Heiko
  • Stenger, Steffen
Venue
The Journal of Immunology
Published
2012-10
Volume
189
Issue
8
Pages
4069-4078
ISSN
  • 0022-1767 (ISSN-L)
  • 1550-6606
OpenAlex
W2143119706
Cited by
112
References
62
Citations by year
2026: 6 · 2025: 3 · 2024: 11 · 2023: 5 · 2022: 5 · 2021: 13 · 2020: 6 · 2019: 11 · 2018: 13 · 2017: 8 · 2016: 12 · 2015: 12 · 2014: 3 · 2013: 4
FWCI
4.20
Type
journal article
Language
en
Open access
Locations
  • The Journal of Immunology (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • European Commission
  • National Institute of Allergy and Infectious Diseases (R01AI047868)
Topics
  • Health Sciences › Medicine › Infectious Diseases › Tuberculosis Research and Epidemiology
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Cellular transport and secretion
  • Health Sciences › Medicine › Epidemiology › Autophagy in Disease and Therapy
Keywords
c-Abl, phagosome acidification, Mycobacterium tuberculosis, macrophages, lysosomal acidification, vacuolar H+-ATPase, imatinib, intracellular bacterial killing, monocytes, drug-resistant tuberculosis, host defense against mycobacteria
MeSH terms
Imatinib Mesylate, Benzamides, Cells, Cultured, Cytoskeletal Proteins, Humans, Hydrogen-Ion Concentration, Mycobacterium tuberculosis, Phagosomes, Piperazines, Pyrimidines, Macrophages, Alveolar, Protein Transport, Protein Kinase Inhibitors, Adaptor Proteins, Signal Transducing

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review